TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04532073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy Therapy
Description: A mindfulness-oriented movement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: A martial art developed in China, which in recent times is often regarded as a system of movement theory or gymnastics

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Treatment process that a clinician should follow for a certain type of patient
Study: NCT04825288

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: XB2001 or Placebo
Description: XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XB2001 or Placebo
Description: XB2001 is a True Human monoclonal antibody that blocks the biological activity of IL-1α with a high degree of affinity and specificity. IL-1⍺ is a key mediator of inflammatory responses and is implicated in the pathophysiology of various diseases, including cancer, cardiovascular and rheumatologic diseases. Ample evidence supports targeting IL-1⍺ to block pathological inflammatory processes associated with many diseases.
Study: NCT05377307

Intervention type: GENETIC
Intervention: Pell's lentiviral-based gene-edited immune cell therapy
Description: No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.

Intervention type: GENETIC
Intervention: Pell's lentiviral-based gene-edited immune cell therapy
Description: No study drug or other planned treatment will be administered. Subjects who previously received Pell's lentiviral-based gene-edited immune cell therapy will be evaluated the safety and efficacy.
Study: NCT05435742

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SON-080
Description: Recombinant human interleukin-6 (rhIL-6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-080
Description: Recombinant human interleukin-6 (rhIL-6)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SON-080
Description: Recombinant human interleukin-6 (rhIL-6)
Study: NCT04732481

Intervention type: PROCEDURE
Intervention: passive leg lift test
Description: passive leg lift test
Study: NCT05384691

Intervention type: DRUG
Group type: OTHER
Intervention: Luspatercept Injection
Description: All formally included patients will receive 1.75 mg/kg luspatercept administered subcutaneously every three weeks (on day 1 of each 21-day cycle) for a duration of 24 weeks.~Responders at the response assessment (according to HI-E) in week 25 will be further treated with 1.75 mg/kg luspatercept until loss of response for an expected maximum of 18 months.
Study: NCT05561530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-125755
Description: single or multiple doses of ALG-125755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or multiple doses of placebo
Study: NCT06429423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute exercise low intensity
Description: A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise low intensity
Description: A 15-minute exercise on low intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acute exercise moderate intensity
Description: A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise moderate intensity
Description: A 15-minute exercise on moderate intensity on a cycle ergometer. Immediately before, immediately after and 30 minutes after exercise participants will fill out questionnaires regarding feelings of fatigue, energy, anxiety and stress and measure saliva cortisol. Three times during the exercise, they will rate level of exertion (RPE) and feelings of distress on a VAS-scale.~During the 24 hours following the exercise bout they will wear a heart rate strap and an accelerometer measuring heart rate variability and activity level. Twice during that time, once in the evening, and once in the morning after, participants will answer questionnaires regarding mood state.
Study: NCT05010083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diet and lifestyle program
Description: See description of main arm.
Study: NCT06423638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Tai Chi Easy
Description: The TCE intervention will be delivered asynchronously online. Participants can complete the classes at a time and in a location that is convenient for them. The classes will be offered for one hour twice weekly and were developed and recorded by a certified Tai Chi Easy practice leader.~TCE is a simple form of mind-body self-care that focuses on four components:~* Mindful movements that help to stretch, and relax the body while improving balance and coordination~* Breathing practices that reduce stress by inducing a relaxation response while improving energy and circulation and enhancing innate healing responses~* Self-applied massage to stimulate blood flow, relax the body, and improve circulation and energy~* Meditation practices to relax the body, center the mind, and calm the emotions
Study: NCT04493320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Description: 150-450mg carbidopa/levodopa 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa
Description: 150-450mg carbidopa/levodopa 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Carbidopa/levodopa-matched placebo tablet 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Carbidopa/levodopa-matched placebo tablet 3 times daily
Study: NCT05896943

Intervention type: DRUG
Intervention: Ustekinumab
Description: Patients with ulcerative colitis treated with ustekinumab
Study: NCT04704024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: oral TDF medication 300 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamivudine Oral Solution
Description: Oral lamivudine with weight-based dosing BID from birth until 6 months of age
Study: NCT05495880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy with forearm-support
Description: forearm-supported head extension during direct laryngoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy without forearm-support
Description: without forearm-support for head extension during direct laryngoscopy
Study: NCT04778748

Intervention type: DIAGNOSTIC_TEST
Intervention: Under-mattress sleep monitor
Description: Under-mattress sleep monitor for patients with a confirmed diagnosis of Obstructive Sleep Apnea.
Study: NCT04739111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
Description: In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
Study: NCT06351839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep-Well despite persistent pain
Description: The Sleep-Well program covers four overarching topics stretched over 7 group sessions (each lasting \~1.5 hours): 1) providing information about sleep physiology, causes of sleep problems, sleep habits and hygiene and use of sleep assessment methods (i.e., sleep diaries) for deciding sleep restriction schedules; 2) behavioural strategies through the application of stimulus control and sleep restriction; , 3) mental strategies by addressing and changing unhelpful (meta)cognitions that commonly occur in sleep and persistent pain conditions; and 4) strategies related to maintenance of good sleep and prevention of relapse. The program has been developed by Diakonhjemmet hospital in Oslo and includes a guideline for therapist and a workbook for patients (that includes home tasks for the participant).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU (treatment-as-usual)
Description: The treatment-as-usual arm represents an active waiting-list arm as subjects receive standard care, which may involve some sleep assessment, rudimentary advice/education about sleep, and possibly also sleep medication. The type of sleep treatment this group receives during the waiting-list period will be recorded from the patients' journal.
Study: NCT04708262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Analytic Therapy for Containing Self-Harm in Young People
Description: The intervention will run over five sessions, each lasting around 30 - 40 minutes. Researchers will follow the CATCH-Y manualised treatment guide. CATCH-Y is a brief, five session psychological intervention based upon CAT principles and designed to help young people who have self-injured.
Study: NCT05217459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-expanding intracranial drug stent system
Description: All patients receive Percutaneous transluminal angioplasty and stenting with self-expanding intracranial drug stent system (Temporary abbreviations: SINOMED IS-DES)
Study: NCT05816746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Dose Decitabine plus anti-PD-1
Description: Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
Study: NCT04799353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC)
Study: NCT05871619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X Pur Remin
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X Pur Remin
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Description: A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye The diode laser was irradiated immediately with 1 W, Exposure time of 10 s, 810 nm, continuous and non-contact mode.
Study: NCT06304025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton's jelly mesenchymal stem cells (WJ-MSCs)
Description: Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton's jelly mesenchymal stem cells (WJ-MSCs)
Description: Four doses of 1x10 6 of thawed allogeneic WJ-MSCs or expanding allogeneic WJ-MSCs / kg at 1, 4, 11, and 18 days
Study: NCT05017974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction plus Prenatal Sleep supplement
Description: MBSR+PS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: TAU

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: TAU
Study: NCT05971654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: azithromycin.:500 mg PO once for 5 days every month
Study: NCT06493149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage therapy
Description: Participants receive a Swedish massage based on the tensegrity principle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Participants receive a Swedish massage based on the tensegrity principle.
Study: NCT04401423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TXA127
Description: 0.5 mg/kg per day
Study: NCT04722159

Intervention type: DEVICE
Intervention: Renal denervation
Description: Catheter-based inhibition of renal sympathetic nerve traffic.
Study: NCT04731870

Intervention type: OTHER
Intervention: Survey research
Description: This is not an intervention study. It involves social science research of surveys and focus groups.

Intervention type: OTHER
Intervention: Survey research
Description: This is not an intervention study. It involves social science research of surveys and focus groups.
Study: NCT06062797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mixed Reality Viewer
Description: The Mixed Reality Viewer from Brainlab (Germany) enables the visualization of the fracture via a 3D hologram. In contrast to virtual reality, where the user is in a completely virtual world, the user of the mixed reality viewer sees the 3D hologram implemented in his real environment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: X-ray or CT scan
Description: X-ray or CT scan enables the visualization of the fracture in 2D.
Study: NCT05915585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy
Description: The patient will receive HILT using the Mectronic Exand MY high-intensity laser system with the following parameters:~Wavelength: 1064 nm (near-infrared) Power: 12 W Energy density: 8 J/cm² Pulse duration: 200 µs Treatment duration: 10 minutes Frequency: 3 sessions per week for 4 weeks Total energy delivered: 96 J per treatment session
Study: NCT04401423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mg/kg per day
Study: NCT06359392

Intervention type: OTHER
Group type: OTHER
Intervention: No message
Description: Participants will not be exposed to a message in this arm of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Culture-centric message
Description: Participants in this arm of the study will watch a 2-minute video on palliative care developed specifically for these American Indian communities.

Intervention type: OTHER
Group type: OTHER
Intervention: General messge
Description: Participants receiving this intervention will watch a 2-minute video developed by the National Hospice and Palliative Care Organization to teach about palliative care.
Study: NCT04799353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV)
Study: NCT06299852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: SRT for metastatic foci
Study: NCT06008431

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS) (active)
Description: The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.
Study: NCT04799353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous (IV)
Study: NCT05808153

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotracer injection
Description: MRI with radiotracer injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotracer injection
Description: MRI with radiotracer injection
Study: NCT05987462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green walking
Description: The researcher provided detailed information to the patients about green walking. For the randomized MI patients, two groups were formed, and they engaged in a 50-minute green walking three days a week for 12 weeks, under the guidance of the researcher. The green walk group's walks were scheduled differently for the two subgroups. The first subgroup had their 50-minute walk on Monday, Wednesday, and Saturday, while the second subgroup had their walks on Tuesday, Thursday, and Sunday. This arrangement ensured a standardized time interval between green walks for both groups.
Study: NCT05717504

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Loop Recorder
Description: Patients will be implanted with a loop recorder. Patients will be given the choice of remove the loop recorder after the 12-months follow-up visit or at the end of its battery life (approximately 3 years)
Study: NCT05134610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEROBIKA POSITIVE EXPIRATORY PRESSURE DEVICE
Description: Intervention arm patients use the OPEP device twice daily for 2 weeks before and after surgery
Study: NCT06049550

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05561933

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Minds Program Foundations Training
Description: The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds Program Foundations Training
Description: The HMP was developed by Healthy Minds Innovations at the UW Center for Healthy Minds, and is based on decades of research on well-being. The program is delivered through a smartphone application and consists of didactic (learns) and experiential (practice) components. Practice components involve contemplative practices such as mindfulness, loving-kindness, and gratitude practices. Each practice allows participants to choose duration (between 5-30 minutes). In addition to sitting style practices common in other meditation apps/programs, the HMP also provides instruction in active practices. Active practices engage the same skills as sitting practice, but focus on strengthening skills during daily routines. Learn components provide psycho-educational content about the science of well-being. HMP learns and practices are based on a four pillar model of well-being skills consisting of Awareness, Connection, Insight, and Purpose.
Study: NCT05386342

Intervention type: DEVICE
Group type: OTHER
Intervention: TufTex Over-the-Wire Embolectomy Catheter
Description: The OTW Catheter can be used for the removal of emboli and thrombi. It can also be used for catheter placement over a guidewire, vessel occlusion, fluid infusion and/or aspiration.
Study: NCT05578989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality glasses
Description: watching a video with music with virtual reality glasses.
Study: NCT04457128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-Time Adaptive Intervention
Description: Randomized factorial design
Study: NCT05262413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 Plus Lenvatinib
Description: QL1706 5mg/kg administered intravenously (IV), every 3 weeks, plus Lenvatinib 20 mg or 14mg administered orally, once daily.